Research programme: transdermal hydrogel patch therapeutics - Alliqua

Drug Profile

Research programme: transdermal hydrogel patch therapeutics - Alliqua

Alternative Names: Alliqua Hydrogel technology; Lidocaine hydrogel patch; Transdermal pain patch - Alliqua

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alliqua
  • Class Acetanilides; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postherpetic neuralgia

Most Recent Events

  • 20 Apr 2017 Discontinued - Preclinical for Postherpetic neuralgia in USA (Transdermal)
  • 24 Oct 2013 Final pharmacokinetics and adverse events data from a preclinical trial in Postherpetic neuralgia released by Alliqua
  • 23 Jul 2013 Research programme: Transdermal hydrogel patch therapeutics - Alliqua is available for licensing as of 26 Jul 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top